menu
    • menu
    [{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"Netcapital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"PPL-138","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Phoenix Pharmalabs \/ Netcapital","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Pharmalabs \/ Netcapital"},{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"PPL-138","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"Phoenix Pharmalabs \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Pharmalabs \/ National Institute on Drug Abuse"}]

    Find Clinical Drug Pipeline Developments & Deals by Phoenix Pharmalabs

    Menu

    Phoenix Pharmalabs

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Phoenix Pharmalabs

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Phoenix Pharmalabs

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naltrexone Analog

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phoenix PharmaLabs’ Lead Compound, PPL-138, Offers Promise as PTSD/AUD Treatment

                            Details : PPL-138 is the small molecule that meets all of our criteria for a potent, safe, non-addicting analgesic and also effective treatment of post-traumatic stress disorder and decreased alcohol consumption.

                            Brand Name : PPL-138

                            Molecule Type :

                            Upfront Cash : Not Applicable

                            September 14, 2023

                            Lead Product(s) : Naltrexone Analog

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Phoenix Pharmalabs

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Phoenix Pharmalabs

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PPL-138

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : $8.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Phoenix PharmaLabs Awarded $8.7 Million Grant from NIDA to Study Compound for Treatment of Cocaine Use Disorde...

                            Details : Funding from the grant will support the study of company’s lead compound, PPL-138, for the treatment of cocaine use disorder (CUD) and the cost of advancing PPL-138 through its remaining preclinical studies and through Phase 1 human clinical trials.

                            Brand Name : PPL-138

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 06, 2022

                            Lead Product(s) : PPL-138

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : $8.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Phoenix Pharmalabs

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Phoenix Pharmalabs

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PPL-138

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Netcapital

                            Deal Size : $1.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Phoenix PharmaLabs Successfully Completes Second Oversubscribed Netcapital Offering

                            Details : Both compounds have also shown promise in preclinical studies as treatments for opioid addiction (PPL-103) and cocaine addition (PPL-138) and the company is pursuing these indications as well.

                            Brand Name : PPL-138

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 23, 2021

                            Lead Product(s) : PPL-138

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Netcapital

                            Deal Size : $1.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth